Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for TGF beta type II- receptor
Most Correlated Studies
- L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
- L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
- L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
- L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
- L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
Most Relevant Literature
- Neuropilin-1 interacts with VE-cadherin and TGFBR2 to stabilize adherens junctions and prevent activ…
- Dexamethasone attenuated thoracic aortic aneurysm and dissection in vascular smooth muscle cell Tgfb…
- Adipose-Derived Mesenchymal Stem Cells-Derived Exosomes Carry MicroRNA-671 to Alleviate Myocardial I…
- Total CD3 T Cells Are Necessary and Sufficient to Induce Colitis in Immunodeficient Mice With Dendri…
- Atractylon Treatment Attenuates Pulmonary Fibrosis via Regulation of the mmu_circ_0000981/miR-211-5p…
Most Relevant Clinical Trials
- Angiotensin II Antagonism of TGF-Beta 1
- Tolerability and Bioavailability of the P144 Peptide Inhibitor of TGF-β1 After Topical Administratio…
- Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
- Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activ…
- Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)
